ACG
HEPA

Allen Capital Group’s Hepion Pharmaceuticals HEPA Stock Holding History

Allen Capital Group’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24
Closed -$47K – 166
2021
Q2 		$47K Hold
24
– – 0.01% 153
2021
Q1 		$44K Hold
24
– – 0.01% 152
2020
Q4 		$52K Buy
+24
New +$62.2K 0.01% 137

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AMC
Asset Management Corp Northbrook, Illinois $128M AUM 6.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Allen Capital Group's HEPA Position: Q3 2021 in Review

Allen Capital Group sold out of Hepion Pharmaceuticals (HEPA) in Q3 2021, closing a stake of 24 shares — an estimated $47K sold.

Allen Capital Group first reported a position in HEPA in Q4 2020 and held it in 3 quarters. The position peaked at $52K in Q4 2020. 37 funds tracked by Wall St. Rank hold HEPA as of Q3 2021.

  • Allen Capital Group reported no remaining Hepion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Allen Capital Group sold 24 Hepion Pharmaceuticals shares in Q3 2021, an estimated $47K.
  • Allen Capital Group first reported a position in Hepion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Allen Capital Group's Hepion Pharmaceuticals position peaked at $52K in Q4 2020.
  • 37 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2021.

Based on Allen Capital Group's 13F filing for Q3 2021, filed 22 Oct 2021.